Pan-cancer study in India finds 24.9% of tumors are MSI-high or MMR-deficient, with 51.2% harboring pathogenic germline variants

◇ RESEARCH

A tumor-first approach applied to 519 patients with colorectal and extracolonic cancers from 17 centers in India (2019–2025) identified MSI-high or MMR-deficient status in 24.9% of tumors, and 51.2% of those patients harbored pathogenic or likely pathogenic germline variants. (Fam Cancer)